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Abstract
Background: Parkinson’s disease is a neurodegenerative disorder characterized pathologically by the loss of
nigrostriatal dopamine neurons that project from the substantia nigra in the midbrain to the putamen and caudate
nuclei, leading to the clinical features of bradykinesia, rigidity, and rest tremor. Oxidative stress from oxidized
dopamine and related compounds may contribute to the degeneration characteristic of this disease.
Results: To investigate a possible role of the phospholipid hydroperoxidase glutathione peroxidase 4 (GPX4) in
protection from oxidative stress, we investigated GPX4 expression in postmortem human brain tissue from
individuals with and without Parkinson’s disease. In both control and Parkinson’s samples, GPX4 was found in
dopaminergic nigral neurons colocalized with neuromelanin. Overall GPX4 was significantly reduced in substantia
nigra in Parkinson’s vs. control subjects, but was increased relative to the cell density of surviving nigral cells. In
putamen, GPX4 was concentrated within dystrophic dopaminergic axons in Parkinson’s subjects, although overall
levels of GPX4 were not significantly different compared to control putamen.
Conclusions: This study demonstrates an up-regulation of GPX4 in neurons of substantia nigra and association of
this protein with dystrophic axons in striatum of Parkinson’s brain, indicating a possible neuroprotective role.
Additionally, our findings suggest this enzyme may contribute to the production of neuromelanin.
Background
Parkinson’s disease (PD) is characterized pathologically
by the development of cellular inclusions called Lewy
bodies composed of aggregated proteins, primarily
a-synuclein (AS) as well as ubiquitin and other mis-
folded proteins. The presence of ubiquitin within these
structures suggests a build-up of proteins that were
directed towards proteolytic degradation. AS also accu-
mulates in the dopaminergic projections from these
neurons forming dystrophic axons. PD is associated
with severe loss of dopamine (DA) neurons in the sub-
stantia nigra (SN) and their striatal terminals, leading to
dopamine depletion and consequential motor impair-
ments. Accumulation of oxidized biomolecules asso-
ciated with degeneration of DA neurons indicates the
involvement of oxidative stress mechanisms [1], and the
highly oxidizable aromatic structure of DA and its meta-
bolites are thought to contribute to these processes [2].
Neurons in SN pigmented with neuromelanin are par-
ticularly sensitive to neurodegeneration in PD [3]. With
aging, SN neurons in primates gradually transition from
dopaminergic neurons, identified by the presence of the
DA-synthesizing enzyme tyrosine hydroxylase (TH), to
dopaminergic neurons expressing neuromelanin and
eventually to cells that do not synthesize dopamine
(TH-negative) but have neuromelanin [4]. The forma-
tion is postulated to require hydroperoxidase activity.
Peroxidase activity associated with neuromelanin has
been demonstrated and is increased in postmortem PD
brain [5]. However, a hydroperoxidase responsible for
neuromelanin formation has not specifically been
identified.
The glutathione peroxidases (GPX) are hydroperoxi-
dases essential for maintaining redox balance in cells [6].
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tain the micronutrient selenium (Se) incorporated as the
amino acid, selenocysteine [7]. Se deficiency results in
impairments in neurological function [8], highlighting
the importance in brain of proteins utilizing this essential
trace element. GPXs have been implicated in PD as brain
glutathione levels are decreased in early stages of PD [9].
As glutathione is a cofactor for the GPX enzymes, its loss
results in decreased peroxidase activity [10]. Overexpres-
sion of GPX1 attenuates 6-OHDA induced toxicity to
dopamine neurons in rodent models of PD [11,12].
A recent study showed that GPX1 is present in human
microglia and may play a role in removing AS aggregates
from neuron terminals [13].
Less is known about the possible role of GPX4 in PD.
Whereas GPX1 reduces inorganic hydrogen peroxide,
GPX4 is the major enzyme that reduces membrane lipid
peroxides [7]. Recent studies indicate the importance of
the phospholipid hydroperoxidase GPX4 in the brain.
Genetic deletion of GPX4 is embryonic lethal [14,15],
and conditional deletion of GPX4 in brain results in
severe neurodegeneration [16], indicating that the role
of GPX4 in lipid hydroperoxide removal is essential for
cell viability. Translation of the GPX4 protein is regu-
lated by DJ-1, a protein implicated in a recessive form
of early-onset PD [17]. Oxidation of DJ-1 is associated
with an increase in cerebral cortex of GPX4 in subjects
with sporadic Parkinson’s disease [18]. However, as
expression of GPX4 has not been investigated in the
brain regions most affected in PD, i.e. the substantia
nigra (SN) and basal ganglia, it is unclear if this upregu-
lation is related to the etiology of PD or secondary to
PD pathology. Lastly, the phospholipid hydroperoxidase
function of GPX4 makes it a candidate enzyme for neu-
romelanin formation.
Here we evaluate the pattern of expression of GPX4 in
the nigrostriatal pathway and whether expression is
altered in PD as a possible response to oxidative stress.
We report that GPX4 is co-localized with neuromelanin
in SN dopamine neurons, decreased in PD midbrain,
and associated with dystrophic axons in PD putamen.
Results
We examined GPX4 in postmortem brain of 12 subjects
that had been clinically diagnosed with PD, as well as 11
subjects without clinical or postmortem pathological
features of PD. Tissue was obtained from the Honolulu-
Asia Aging Study (HAAS). Data for all subjects are sum-
marized in Table 1. There were no significant differ-
ences in age or post-mortem interval (PMI) between
control and PD subjects. However, data obtained at
autopsy demonstrated that the density of cells in SN
was reduced in PD subjects to about a third of controls.
The degeneration was most severe in lateral ventral SN,
where the cell density in PD subjects was approximately
a fifth of control subjects [19].
GPX4 in SN
We tested GPX4 antibody specificity by western blot. As
s h o w ni nF i g u r e1 A ,t h ea n t i b o d yr e a c t e dw i t ha2 2k D
band in protein from human brain and from SH-SY5Y
human neuroblastoma cells. This immunoreactivity was
blocked by preabsorbing the antibody with the recombi-
nant GPX4 antigen. However, the antibody did not
recognize protein in extracts from the mouse N2A neu-
roblastoma cell line, and reacted with additional bands
in mouse cortex protein. Thus the antibody appeared to
Table 1 Study Subjects
Control (n = 11) PD (n=1 2 )
Age Range (YR): 76.6-91.7 79.6-92.9
Age at Death (YR): 84.0 ± 1.3 84.2 ± 1.0
Post-Mortem Interval (HR): 17.01 ± 2.7 9.57 ± 4.1
Median (and Range) Braak stage: 0 (0) 5.5 (5-6)
Total SN Cell Density: 21.7 ± 1.9 8.2 ± 1.4
†
Lateral-Ventral SN Cell Density: 27.6 ± 3.3 5.2 ± 1.6
†
† indicates significantly different from controls (P < 0.0001).
HAAS subject information obtained at autopsy. Methods published
previously [19].
All decedents were American-born males of Japanese ancestry living in
Hawaii. Data are mean ± SEM unless indicated otherwise.
Figure 1 GPX4 is associated with neuromelanin in SN neurons.
GPX4 colocalizes with neuromelanin in SN of control brain.
A. Western blot showing antibody specificity in human brain (left) and
human and mouse neuroblastoma cells and mouse cortex (right). For
“blocked” controls, antibody was preabsorbed with original
recombinant antigen. B. Immunohistochemistry negative control with
primary antibody omitted. Brown pigment is endogenous
neuromelanin (black arrows). C. Robust GPX4 expression (dark grey
Ni-DAB, white arrowheads) is associated with neuromelanin (brown,
black arrows) and in the cytoplasm (*). D. Enlarged cell images,
counterstained with methyl green to show nuclei of these neurons
(white arrows). Scale bars: B, C, 20 μm, D, 10 μm.
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mouse cells and tissue.
We examined subcellular localization of GPX4 in SN
in control brain using immunohistochemistry. GPX4
was mostly colocalized with neuromelanin in SN neu-
rons (Figure 1C). SN neuromelanin can be clearly seen
when primary antibody is omitted (Figure 1B). GPX4
immunolabeling with 3, 3-diaminobenzidine hydrochlor-
ide (DAB) containing NiCl2, in order to contrast with
neuromelanin, coincided mostly within neuromelanin-
positive neurons, and surprisingly was mostly associated
with intracellular neuromelanin (Figure 1C, D). Weaker
labeling of other cytoplasmic areas in these neurons is also
present (shown by white asterisks), but some cytoplasmic
regions were void of GPX4 immunoreactivity and
appeared as empty space (black asterisks). Co-localization
of GPX4 with neuromelanin was observed in midbrain
sections from all 11 control and 12 PD subjects,
although neuromelanin was notably reduced in SN of
PD midbrain, presumably due to loss of neuromelanin-
containing neurons. GPX4 labeling was also present at
low levels in tissue surrounding neurons, in smaller
glia cells (black arrowheads) and in midbrain white
matter fibers (not shown).
We used spectral imaging to compare GPX4 immu-
noreactivity in SN cells with presence or absence of
neuromelanin. Figure 2A depicts a group of TH-positive
cells that are negative for neuromelanin. GPX4 immu-
noreactivity is largely absent in these cells, although it
can be seen in surrounding glia and white matter. Figure
2B shows a group of TH- and neuromelanin-positive
neurons. GPX4 immunoreactivity was visible in most
TH-positive cells expressing neuromelanin, although
expression levels varied from cell to cell. Figure 2C
shows a group of TH-negative, neuromelanin-positive
cells. GPX4 labeling was strongest within these cells.
These findings suggest GPX4 expression increases in SN
neurons with the development of neuromelanin and
continues to increase as expression of TH is lost.
GPX4 in PD SN
We examined GPX4 immunoreactivity in SN of PD and
control brain and its relation to Lewy bodies using an
antibody to alpha synuclein. We found GPX4 associated
with AS-positive Lewy bodies (Figure 3A), which were
often found within or bordering cellular regions of
GPX4/neuromelanin. This is in agreement with the
association of GPX4 with neuromelanin, as Lewy bodies
have some association with neurons that have high neu-
romelanin content [3]. Confocal sections though tissue
with a thickness of 0.9 μm showed that GPX4 labeling
present within Lewy bodies (3B, above), although gener-
ally less than in surrounding cytoplasm and typically
confined to the perimeter of the inclusions (3B, below).
Figure 2 GPX4 is found primarily in Neuromelanin-expressing
neurons of SN. GPX4 immunoreactivity is present in most cells
expressing neuromelanin but is absent in many cells expressing TH
but not neuromelanin. A. Example of cells expressing TH but not
neuromelanin. Light microscope images (above left) were filtered
for neuromelanin (blue, above center) to compare with TH
immunoreactivity (magenta, above right) and GPX4
immunoreactivity (green, below left). GPX4 images combined with
neuromelanin (below, middle) and TH immunoreactivity (below,
right) are also shown for comparison. GPX4 is present in
surrounding glia but absent in TH-expressing neurons. B. Examples
of TH and neuromelanin expressing neurons. GPX4 is present in
most cells with neuromelanin. C. GPX4 immunoreactivity is
prominent in neurons containing neuromelanin but no longer
expressing TH. (Note: as images were not taken with confocal
microscopy, color changes only show only co-localization of area
and not intracellular co-localization). Scale bars: 20 μm.
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by measuring area of immunoreactivity using unbiased
stereology. Using a Cavalieri probe, we determined that
GPX4 was significantly decreased in SN of PD brain
compared with control SN (Figure 4A, B). The total
volume fraction of GPX4 immunoreactivity in this
region was reduced by nearly one third in PD brain,
from 0.036 ± 0.004 in control SN (n = 11) to 0.024 ±
0.003 in PD SN (n = 12).
The reduction in total GPX4 immunoreactivity could
be due to the severe cell loss in this region. In order to
determine if loss of GPX4 could be explained by cell
death, we investigated the volume of GPX4 as a func-
tion of cell density. We found that GPX4 immunoreac-
tivity is actually increased relative to the cell density of
surviving SN neurons (Figure 4C). GPX4 volume den-
sity is increased from 0.0018 ± 0.0002 in controls (n =
11) to 0.0038 ± 0.0007 in PD (n = 12) (P = 0.0192),
indicating that GPX4 is either upregulated in surviving
neurons or that a greater percentage of cells not
expressing GPX4 are lost compared to cells with
GPX4. This suggests a neuroprotective role for GPX4
within these neurons.
GPX4 in Putamen
In putamen, GPX4 is associated with small cell bodies
reminiscent of small stellate neurons or glia (Figure 5A).
GPX4 immunoreactivity was not significantly different
between normal and PD putamen (Figure 5B). The area
Figure 3 GPX4 in nigral inclusions of PD brain.A .G P X 4
expression (dark grey Ni-DAB, white arrowheads) coincides with AS-
positive Lewy bodies (blue BCIP, marked by black arrowheads) in SN.
Black arrows indicate neuromelanin. B. Confocal microscope images
of two cells showing relationship of GPX4 (green) to AS (magenta).
The above example shows some co-localization of GPX4 with AS
within a Lewy body, while the below example shows GPX4 only
around the Lewy body perimeter. Scale bars: A, 20 μm, B, 10 μm.
Figure 4 GPX4 is reduced overall but increased relative to cell
density in PD SN. A. GPX4 (dark grey) is visibly reduced in SN of
PD subjects (n=1 2 ) compared to controls (n=1 1 ). B. Total
immunoreactivity of GPX4 is significantly reduced in SN of PD
subjects compared to controls (P = 0.0398, Student’s t-test). C. GPX4
immunoreactivity is increased relative to cell density (P = 0.0192,
Student’s t-test). Scale bars: 20 μm.
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putamen compared to controls, but the increase was not
significant (Figure 5C). As PD-associated neurodegen-
eration is specific to DA axons from SN and not cell
bodies in putamen, this finding supports a loss of GPX
that is specific within DA neurons.
To determine if GPX4 was found in DA terminals, we
used double-labeling immunohistochemistry with GPX4
and an antibody to tyrosine hydroxylase (TH). In non-
PD putamen sections, GPX4 immunoreactivity (blue/
gray) was generally not associated with TH-positive
(red) fibers in control brain (Figure 5C, left), although
weaker levels of GPX4 immunoreactivity are possible.
Instead, GPX4 was mostly associated with smaller cells
within putamen that are likely to be stellate neurons or
glial cells. PD putamen contained relatively few
TH-positive fibers and terminals, and some of the
TH-positive axons were varicose and truncated (5D,
right). Some GPX4 immunoreactivity was associated
with the dystrophic axons in PD putamen (Figure 5D,
lower right), in contrast with the lack of GPX4 found in
TH-positive terminals in non-PD subjects.
We used confocal microscopy to further examine the
relationship between GPX4 and TH in putamen axons
(Figure 6). As described for light microscopy, we found
little colocalization of GPX4 with TH in putamen sam-
ples from non-PD subjects. However, we found GPX4
concentrated in dystrophic axons and colocalization of
GPX4 with TH in axonal varicosities (shown by white
arrowheads). This suggests an upregulation of GPX4 in
degenerating dopaminergic terminals.
Altogether, these findings indicate changes in GPX4 in
SN and putamen that coincide with PD pathology, sug-
gesting a role for GPX4 in the development of this
disorder.
Discussion
In this study, we have determined that altered GPX4
levels and distribution are associated with pathological
PD changes. Specifically, overall GPX4 is greatly reduced
in the SN of PD vs. control subjects, but when cell loss is
taken into account, GPX4 is increased relative to cell
density. Interestingly, GPX4 immunoreactivity is asso-
ciated with neuromelanin in SN and colocalizes with
AS-positive nigral Lewy bodies and dystrophic TH-positive
fibers in putamen. These findings indicate either an
Figure 5 GPX4 expression in putamen. A. GPX4 immunoreactivity
is detectable in cell bodies in the putamen of control brains (white
arrowheads). B. Comparison of GPX4 labeling in normal and PD
putamen. C. Mean GPX4 volume fraction is higher in PD (n=1 2 )
putamen compared to control putamen (n=1 1 ), although the
difference is not significant (P > 0.05). D. Images of TH (Nova Red,
red color, marked by black arrows) and GPX4 (DAB-Ni, blue/gray,
white arrowheads) in putamen of non-PD (left) and PD (right) brain.
Occasional swollen, dystrophic axons are present among the
relatively few TH-positive fibers and terminals in PD putamen. Scale
bars: 20 μm.
Figure 6 GPX4 is associated with dystrophic axons in PD
putamen. Confocal images of GPX4 (blue) and TH (magenta) in non-
PD (and PD brain (F, H, J). GPX4 has little association with TH in
control brain sections, but colocalizes with TH in dystrophic axons in
PD brain (shown by white color, white arrowheads). Scale bar: 10 μm.
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increase in survival of cells expressing GPX4, and further
suggest a neuroprotective role of GPX4 in PD pathology.
GPX4 has recently been shown to prevent 12/15-
lipoxygenase-dependent apoptotic cell death resulting
from oxidative stress [16]. In the absence of GPX4, lipid
peroxidation via 12/15-lipoxygenase leads to activation
of the apoptosis-inducing factor (AIF) to induce cell
death. Thus GPX4 is an important factor to prevent
neuronal death from the increased lipid peroxidation
found in PD neurons. However, GPX4 may be less effec-
tive in PD brain as glutathione levels are reduced early
in the disorder [9]. This could lead to overproduction of
GPX4 without the benefit of reduced oxidative stress
and lead to its association with pathological structures.
Colocalization of GPX4 with neuromelanin is particu-
larly suggestive of a role for GPX4 in aging of DA
neurons. As GPX4 is a lipid hydroperoxidase [20], colo-
calization with neuromelanin suggests GPX4 could be a
hydroperoxidase contributing to the synthesis of neuro-
melanin. The function of neuromelanin is currently
unknown, but it is relevant that the substance accumu-
lates in the SN of aging primates [4,21]. Neuromelanin
is specific to catecholaminergic neurons of higher mam-
mals, and SN neuromelanin is comprised of repeats of
quinone structures which are likely formed from oxi-
dized dopamine as well as dopamine synthesis or break-
down structures such as L-DOPA and DOPAC [21-23].
In a previous proteomics study, GPX4 was identified as
a protein associated with neuromelanin in human brain
[24]. Buildup of neuromelanin may be toxic to cells
[25], although there is some evidence that it has a pro-
t e c t i v er o l ei nt h e s en e u r o n s [26]. The colocalization of
GPX4 with neuromelanin could indicate a response to
oxidized lipids associated with neuromelanin. As neuro-
melanin is made up of lipids, protein and fatty acids,
GPX4 may associate with neuromelanin in order to
reduce the associated oxidized molecules. Conversely, an
association of GPX4 with neuromelanin may result in a
buildup of oxidized glutathione, further depleting the
active pool of glutathione in PD.
The association of GPX4 with TH-positive degenerat-
ing axons in putamen suggests an up-regulation of
GPX4 at the level of the putamen. A buildup of oxidized
dopamine in axons could possibly induce expression of
GPX4 to mitigate oxidative stress. An increase in GPX4,
specific to dystrophic axons, could explain the apparent
increase in GPX4 in putamen, which may be masked by
a lack of change in cell bodies of neurons intrinsic to
putamen. Furthermore, it seems possible that the
changes in GPX4 in dystrophic neurons could be related
to the colocalization of GPX4 with neuromelanin.
Up-regulated GPX4 may accumulate in cell bodies, or
may be transported from fibers as axons retract. The
increase in GPX4 in soma may catalyze formation of
neuromelanin from increased dopamine quinone in
these neurons. Thus GPX4 may have an important role
in the development of PD pathology.
Conclusions
We have developed a model of the possible competing
reactions of GPX4 in reduction of lipids and production
of neuromelanin, depicted in Figure 7. GPX4 uses
g l u t a t h i o n ea sas u b s t r a t et or e d u c eo x i d i z e dl i p i d s
(above) [15]. However, a build-up of oxidized forms of
DA-related compounds such as DA-quinones may drive
the synthesis of neuromelanin from these compounds, a
process that may compete with reduction of lipids
(below) [21-23]. Depletion of glutathione and upregula-
tion of GPX4 peroxidase activity in response to oxidative
stress may further drive the production of neuromelanin
Figure 7 Possible Role of GPX4 in Prevention of Apoptotic Cell
Death and Production of Neuromelanin. In healthy DA neurons,
GPX4 functions to reduce oxidized lipids by oxidizing glutathione
(GSH) to glutathione disulfide (GSSG) (above). However, a buildup of
oxidized dopamine metabolites or a reduction of glutathione may
lead to the synthesis of neuromelanin by GPX4, a process that
could compete with reduction of oxidized lipids (below). The
accumulated oxidized lipids will be metabolized by 12/15-
lipoxygenase (12/15-lipoxy) and may eventually induce AIF and
promote apoptotic cell death of DA neurons.
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lipids are metabolized by 12/15-lipoxygenase, and meta-
bolite products activate AIF to promote apoptotic cell
death [16]. Thus under pathological conditions such as
extreme levels of oxidation, the important protective
properties of GPX4 may be redirected towards neurome-
lanin production, and this process may contribute to the
loss of DA neurons in PD. Overall, our findings indicate
an important neuroprotective role for GPX4 in neurons
of the nigrostriatal pathway, and also suggest a role in
neuromelanin synthesis associated with primate aging.
Methods
Subjects
Formalin-fixed human brain tissue was provided by the
Honolulu-Asia Aging Study (HAAS), an ongoing longi-
tudinal epidemiological study that has monitored the
health and lifestyle of a cohort of Japanese-American
men born between 1900 and 1919 and residing on
Oahu, Hawaii [27]. Sections (10 μm) of SN and putamen
from 12 subjects clinically diagnosed with PD and hav-
ing marked pathological features including Lewy bodies
and degeneration of dopaminergic terminals and cell
bodies were examined. Sections from 11 age-matched
subjects that had no symptoms of PD during life and no
PD-associated neuropathology were used as controls in
this study.
Western blot
Post-mortem tissue from human occipital cortex was
homogenized by sonication in 10 mM Tris/1 mM
EDTA/protease inhibitor cocktail (1:1000; Sigma, St.
Louis, MO), centrifuged at 1,000 × g for 10 min, and
protein concentration in the supernatant was measured
using Pierce BCA kit (Rockford, IL). Proteins were sepa-
r a t e db yS D S - P A G Ea n dt r a n s f e r r e dt on i t r o c e l l u l o s e .
Protein was extracted from SH-SY5Y cells, N2A cells
and mouse cortex using CellLytic buffer (Sigma) per
manufacturer’s instructions, separated by electrophoresis
and blotted to PVDF membranes. Blots were blocked
with Odyssey blocking buffer (LiCore Biosciences) for
1 hr and then incubated in GPX4 antibody (AbFrontier)
diluted 1:2000. To confirm antibody specificity, antibody
blocked with 50 μg/ml recombinant GPX4 antigen
(AbFrontier) was also used. After washing with PBS
containing 0.05% tween-20 (PBST), membranes were
treated with secondary antibodies labeled with infrared
fluorophores (LiCore Biosciences). After further washes
in PBST, blots were imaged with the Odyssey infrared
imaging system (LiCore Biosciences).
Immunolabeling
Immunolabeling was performed as described previously
[28]. Samples were de-paraffinized and antigens
unmasked by heating in a pressure cooker to 95°C and
15 psi for 20 min in Trilogy alkaline solution with
EDTA (Cell Marque), followed by 3 min in 90% formic
acid. Samples were then blocked in PBS with 5% serum,
species matched to secondary antibody. Tissue was incu-
bated in rabbit polyclonal anti-GPX4 (1:800, AbFrontier)
overnight at 4°C in 3% serum. After washes, sections
were incubated in biotinylated secondary antibody fol-
lowed by ABC™ reagent. HRP signals were developed
with 3, 3-diaminobenzidine hydrochloride (DAB, Vector
Labs), with or without the addition of nickel chloride to
darken color as per manufacturer’s instructions.
Double Immunolabeling
Following first primary antibody, tissue was subse-
quently blocked in 5% normal horse serum, followed
with separate blocking steps in streptavidin and biotin
solutions (from ABC kit) five minutes each before
second primary antibody reaction. Additional primary
antibodies used were anti-a-synuclein (AS) (1:1000,
Chemicon or 1:50, Abcam) and anti-tyrosine hydroxy-
lase (TH, 1:8000, Sigma). Combinations of HRP-labeled
secondary antibodies detected with DAB, DAB contain-
ing nickel chloride (DAB-Ni) or Nova Red reactions
(Vector Laboratories), or alkaline phosphatase (AP)
detected with BCIP reactions, were used to maximize
contrast between the different antibodies.
Fluorescent Immunolabeling
Depariffinization, antigen unmasking and primary anti-
body labeling were performed as described above. After
washes, tissue was incubated in secondary antibodies
conjugated to Alexa 488 and Alexa 546. Endogenous
fluorescence was reduced by treating with an autofluor-
escence eliminator reagent (Chemicon).
Spectral Imaging and Confocal Microscopy
Bright light and fluorescent images of midbrain tissue
samples were imaged using an Olympus microscope
equipped with the Nuance multispectral imaging system
(Cambridge Research and Instrumentation, Inc). After
obtaining spectral libraries for bright light images of unla-
beled tissue and neuromelanin and fluorescent images of
fluorophores and background autofluorescence, brightfield
and fluorescent images were “unmixed” into individual
signal components (i.e. neuromelanin or fluorescent
probes) that were pseudocolored for comparison.
Confocal images were collected with a Zeiss LSM Pas-
cal laser confocal microscope and analyzed with ImageJ
software.
Stereology
Volume-density of immunolabeling was determined
with a Cavalieri probe using Stereologer software
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putamen) was outlined using 5× magnification, and a
computer-generated array of systematic-random loci
were then visited and observed under 40×. A Cavalieri
probe was placed over 50% of the image with an array
of points (+), and the fraction of points contacting
immunolabeled cells were used to estimate the area
fraction of immunolabeling at that location. The total
area fraction of immunolabeling was estimated as the
average area fraction of all systematic-randomly chosen
sites. According to the Delesse principle, area fraction
on random sections is equivalent to the volume
fraction [29].
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